Johnson & Johnson · NYSE:JNJ

Johnson & Johnson — Corporate Update (May 2024)

12 slides from Johnson & Johnson's corporate update, May 1, 2024

  1. Slide 1: Johnson & Johnson Announces Proposed Plan by LLT Management to Resolve its Talc Litigation

    Johnson & Johnson Announces Proposed Plan by the Company’s Subsidiary, LLT Management, to Resolve its Talc Litigation Johnson&Johnson

  2. Slide 2: Jessica Moore, Vice President, Investor Relations

    Jessica Moore Vice President, Investor Relations

  3. Slide 3: Cautions Concerning Forward-Looking Statements

    Cautions Concerning Forward-Looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the proposed prepackaged Chapter 11 bankruptcy plan. The viewer is cautioned not to rely on these forward-looking statem

  4. Slide 4: Joaquin Duato, Chairman and Chief Executive Officer

    Joaquin Duato Chairman and Chief Executive Officer J&J

  5. Slide 5: Our Credo

    Notre Credo Neogene setters at Semi ee det ‘hide tae tes etn SCtenane pono pete tan to ae] ee else. Sve PE Johnson&Johnson BIER Bom os. BE fo. nM eUCHR, Teeeants. BR) FRcOnBSRAEAL roamed. 83) femnevannies Raounieonl. © (eae arnis aronaomes. Kenacnreeo: aoeeoce. ser iBAReReLG! qamaacest, pert. paoaen

  6. Slide 6: Erik Haas, Worldwide Vice President, Litigation

    Erik Haas Worldwide Vice President, Litigation J&J

  7. Slide 7: The Plan enables the Company to resolve its talc litigation

    The Plan enables the Company to resolve its talc litigation and is in the best interests of ovarian claimants J&J The Plan is focused on current and future ovarian talc claims and would resolve 99.75% of all pending talc lawsuits The Company has already resolved 95% of the mesothelioma lawsuits file

  8. Slide 8: Joe Wolk, Executive Vice President, Chief Financial Officer

    au Joe Wolk = Executive Vice President, Chief Financial Officer J&J

  9. Slide 9: Financial reconciliation of the Company's reserve balance

    Financial reconciliation of the Company’s reserve balance Q4 2023 Reserve ~$9 billion Q1 2024 Charge $2.7 billion Q1 2024 Payments $(0.6) billion Q1 2024 Present Value of Reserve ~$11 billion Total Nominal Value of Reserve ~$13.7 billion J&J

  10. Slide 10: Multi-faceted capital allocation strategy fueling future innovation and returns to shareholders

    Multi-faceted capital allocation strategy fueling future innovation and returns to shareholders Capital allocation Higher Priority Organic growth business needs Free cash flow! Competitive dividends Investment in M&A Lower Share repurchases priority Priorities are clear and remain unchanged J&J ess

  11. Slide 11: Questions

    Questions Johnson&Johnson

  12. Slide 12: Johnson&Johnson

    Johnson&Johnson

Johnson & Johnson — Corporate Update (May 2024) on 6ix